$PFSA

Profusa, Inc.

Profusa is a digital health technology company based in Berkeley, California. It develops a biosensor platform using injectable subcutaneous hydrogel sensors, a reusable optical reader, software algorithms and mobile applications to measure and display real-time biochemical data. Its Lumee platform includes Lumee Oxygen, which measures tissue oxygen and is used for wound care monitoring, and Lumee Glucose, a continuous glucose monitoring platform for people with diabetes. Lumee Oxygen has CE approval in the European Union; Lumee Glucose is not authorized for commercial sale in any jurisdiction, and Profusa has no U.S. regulatory approval for product sales. Profusa designs, develops and manufactures Lumee Oxygen and aims to commercialize it in Europe and, subject to regulatory approval, the United States. Its product development also targets other analytes, including lactate, CO2, ethanol and pH. Profusa plans to partner with healthcare and technology platforms to provide data streams from its sensors.

AlphAI earnings readQ2 FY2026 · AUG 20Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision LabsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
1
0

No SEC Form 4 filings for $PFSA in the last 30 days.

See all $PFSA insider activity →
Low

Profusa 3Q 2026: EPS ($6.23) — 10-Q Summary

Profusa reported no revenue in Q3 2026, with net loss narrowing 81% YoY to $4.95M, and EPS at ($6.23). Expenses fell due to workforce reduction and lower costs. The company received ISO 13485:2016 certification for its Lumee Oxygen Platform.

Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth under Item 2.03 below is hereby incorporated herein by reference. Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Note Mo

PFSA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning PFSA (Profusa, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent PFSA coverage spans corporate actions, regulation and earnings.

What's driving PFSA

AlphAI scores every news story that mentions PFSA with an AI model for sentiment and relevance, and aggregates insider trades from Profusa, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PFSA

Score

A certificate lets Profusa start making sensors that track oxygen in body tissue.

Profusa, Inc. (PFSA) received ISO 13485:2016 certification from GMED, a step toward MDR certification and CE marking for its Lumee Oxygen Platform. The certification covers the design, development, and manufacture of the platform at its Berkeley facility. Profusa aims to begin manufacturing the platform and pursue commercial distribution in the EU, subject to regulatory approvals.

$PFSAMedOffering· $700K

Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia

Biotech Stocks On The Move - APUS, PFSA, GCTK, ARCT

Biotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.

Profusa Advances Lumee Oxygen Platform Toward CE Mark

Profusa (PFSA) received a positive ISO 13485 decision from GMED, advancing its Lumee Oxygen Platform toward CE marking in the EU. The platform monitors tissue oxygen levels. Profusa expects ISO certification in early October but cautions on timing uncertainties. PFSA stock is up 86.82% in pre-market trading.

Related tickers